BrainsWay Ltd. (BWAY) Stock

About BrainsWay Ltd.

BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

BrainsWay Ltd. is headquartered in IL.

BrainsWay Ltd. (BWAY) stock trades at $16.56 with a market capitalization of $649.53M. The stock is valued at a price-to-earnings (P/E) ratio of 72.48, price-to-book of 8.22, price-to-sales of 10.83. Over the past 52 weeks the stock has ranged between $5.68 and $17.35, and currently trades 4.6% below its 52-week high.

On profitability, BrainsWay Ltd. generates a return on equity (ROE) of 12.28%, return on capital employed of 6.54%, an operating margin of 10.09%, a net profit margin of 14.57%.

Official website: www.brainsway.com

BrainsWay Ltd. by the numbers, 2016–2025

Between 2016 and 2025 BrainsWay Ltd. reported revenue of $12.0M rising to $52.0M, a change of +333.3% across 10 years. Compounded, revenue has grown 18.8% a year over five years, 24.4% over three, 26.8% over the last twelve months. Net profit rose to $8.0M.

Operating margin went from -17.9% in 2016 to 8.3% in 2025, a gain of 26.2 percentage points. The most recent net margin is 14.57%. On a trailing twelve-month basis to Mar '26, revenue is $58.0M and net profit $9.0M.

Borrowings rose from $1.0M to $7.0M, cash on hand is $59.8M, cash from operations was $18.0M in the latest year, positive in 4 of the last 10.

Return on equity has averaged -6.6% over five years, and was 11.0% in the most recent year.

The share price itself has compounded at 29.7% a year over five years, 140.0% over three, 173.7% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

BrainsWay Ltd. (BWAY) — frequently asked questions